{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06394414","nct_id":"NCT06394414","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06394414. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy","label":"Part 1: Dose escalation","type":"EXPERIMENTAL"},{"description":"YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy","label":"Part2: Cohort Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-04-29","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors"],"enrollment":{"count":187,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"YL201","otherNames":["Serplulimab","Platinum"],"type":"DRUG"}],"last_update":"2026-06-25","lead_sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","official_title":"A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Serplulimab With or Without Platinum-based Chemotherapy in Selected Subjects With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-04-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Evaluate the AEs in YL201 combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors","timeFrame":"Approximately within 36 months"},{"measure":"To determine the MTD/RED of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors","timeFrame":"Approximately within 36 months"},{"measure":"To evaluate the efficacy of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors based on ORR","timeFrame":"Approximately within 36 months"},{"measure":"To determine the RP2D of YL201 in combination with serplulimab with or without platinum-based chemotherapy in advanced solid tumors based on ORR","timeFrame":"Approximately within 36 months"}],"references":[],"start_date":{"date":"2024-04-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06394414"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06394414"}